AnaCipher receives ANVISA approval for clinical and bioanalytical facilities

AnaCipher, a Hyderabad-headquartered Clinical Research Organisation (CRO) owned by Indoco Remedies, has received approval from Brazil’s National Health Surveillance Agency (ANVISA) for its clinical and bioanalytical facilities.

The approval follows an ANVISA inspection conducted between March 30 and April 7, 2026. It authorizes AnaCipher to conduct bioavailability and bioequivalence (BA/BE) studies and provide associated bioanalytical support for submissions to the Brazilian regulator.

This clearance allows the CRO to support sponsors developing dossiers for Brazil, the largest pharmaceutical market in Latin America, and positions the company to support filings across the wider region. Aditi Panandikar, Managing Director of Indoco Remedies, stated that the approval reflects the CRO’s quality management systems and adherence to international regulatory and Good Clinical Practice (GCP) standards.